A meta-analysis study that included 13 trials evaluated the effect of CoQ10 supplements on ejection fraction (EF) and New York Heart Association (NYHA) functional classification in heart failure patients. The trials included men and women age 49 to 68 years old who had baseline blood CoQ10 concentrations ranging from 0.61 to 1.01 ug/mL and EF ranging from 22 to 46%. Pregnant women were excluded from the studies. The treatment group received a dose of CoQ10 ranging between 60 to 300 mg for 4 to 28 weeks. CoQ10 supplementation resulted in an average increase of 1.4 ug/mL in blood CoQ10 levels. The EF increased by 3.67% and there was a slight improvement in NYHA classification. The main side effect associated with CoQ10 administration was an upset stomach.
Coenzyme Q10 blood and tissue levels are reduced by aging and cardiovascular disease. Individuals with hypertension may have low blood levels of CoQ10. A meta-analysis of 12 clinical trials was conducted to evaluate the efficacy of CoQ10 in reducing blood pressure (BP). The investigators concluded that CoQ10 supplementation in hypertensive patients may reduce systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg.
Isolated Systolic Hypertension
More than 50 million adults have isolated systolic hypertension, which increases the risk of cardiovascular-related deaths. A randomized, double-blind, placebo-controlled study demonstrated that the use of CoQ10 60 mg/day for 12 weeks decreased SBP by 17.8 mm Hg.
A randomized controlled trial evaluated the effects of CoQ10 in people who recently had a heart attack. The study included patients who were admitted to the hospital for possible heart attack, including unstable angina. They were randomly assigned to receive CoQ10 120 mg daily or placebo (B vitamins) for 28 days. All subjects also received standard of care with streptokinase, nitrates, aspirin, diltiazem, and metoprolol. Patients who received CoQ10 showed significant improvement in chest pain (9.5% vs. 28.1%), abnormal heart rhythms (9.5% vs. 25.3%), and poor left ventricular function (8.2% vs. 22.5%). The CoQ10 group also demonstrated a significant reduction in cardiac events (15% vs. 30.9%), including cardiac deaths and heart attacks.
Ischemic Reperfusion Injury
Some clinical studies evaluated whether taking CoQ10 by mouth or intravenously for 1 week before heart surgery can decrease hypoxic damage during surgery. One study suggested that taking CoQ10 300 mg/day for 2 weeks before cardiac bypass surgery increases CoQ10 levels and may improve mitochondrial efficiency and increase the ability of the heart muscle to withstand hypoxia-reoxygenation stress.
More Uses For CoQ10